Clinical Trial

Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases

Study acronym: BAH247
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated November 5, 2024 (before its estimated December 10, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is an open, single-arm, clinical study to evaluate the efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) targeting BCMA or CD19 or both sequentially in the treatment of Relapsed/ Refractory Autoimmune Disease such as Sjogren's Syndrome or Systemic Lupus Erythematosus and other Autoimmune Disease.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-05-20; most recent amendment 2024-11-04.
Status change: Not Yet Recruiting → Recruiting 2024-05-29
Trial Details
NCT Number NCT06428188
Lead Sponsor Essen Biotech
Conditions Autoimmune Diseases, Systemic Lupus Erythematosus, Systemic Lupus Erythematosus Acute, Sjogren's Syndrome
Enrollment 60 participants
Start Date 2024-05-29
Primary Completion 2025-12-10 (estimated)
Study Completion 2026-12-28 (estimated)
Updated on ClinicalTrials.gov 2024-11-05